Opinion: MAPGuide: A tool to help improve health-related public-private partnership agreements
Whenever a new infectious outbreak threatens global health, pharmaceutical companies, governments, international organizations, and philanthropies scramble to develop new vaccines. But intellectual property, price, and other access provisions can get in the way.
Building on the lessons of the 2014 Ebola outbreak in West Africa and propelled by the urgent need for Covid-19 vaccines, the private and public sectors have made enormous progress in responding to pressing public health needs. New partnerships such as the Coalition for Epidemic Preparedness Innovations and COVAX have advanced the development and procurement of vaccines for the greater global good.
